Effects of substance use disorder on treatment process and outcome in a ten-session psychiatric treatment for borderline personality disorder

Abstract Background Dual diagnosis is common in Borderline Personality Disorder (BPD), one of the most common being Substance Use Disorder (SUD). Previous studies have shown that general psychiatric management (GPM) was effective in reducing borderline symptoms. In the present study, we tested wheth...

Full description

Bibliographic Details
Main Authors: Louise Penzenstadler, Stéphane Kolly, Stéphane Rothen, Yasser Khazaal, Ueli Kramer
Format: Article
Language:English
Published: BMC 2018-02-01
Series:Substance Abuse Treatment, Prevention, and Policy
Online Access:http://link.springer.com/article/10.1186/s13011-018-0145-6
Description
Summary:Abstract Background Dual diagnosis is common in Borderline Personality Disorder (BPD), one of the most common being Substance Use Disorder (SUD). Previous studies have shown that general psychiatric management (GPM) was effective in reducing borderline symptoms. In the present study, we tested whether the short GPM was as effective in the BPD + SUD as in the BPD group. Methods We analysed a group of 99 patients presenting a BPD. 51 of these patients presented a SUD. The BPD group and the BPD + SUD group received a manual-based short variant of the GPM treatment. Previous studies have shown that a 10-session version of GPM was effective in reducing borderline symptoms at the end of the treatment (Psychother Psychosom 83:176–86, 2014). Results We found no significant difference in the reduction of general symptoms, which diminished in both groups. The specific borderline symptoms were also reduced in both groups, but there was a slightly higher reduction of the borderline symptoms in the SUD group. The therapeutic alliance progressed positively in all groups. Moreover, the alliance increased more over time in the SUD group. Conclusion The short variant of GPM seems to be effective in BPD treatment independently from the presence of SUD. Therefore, this treatment could be an effective entry-level treatment for patients with dual diagnosis as well as patients with BPD only. Further studies are needed to confirm efficacy and long-term outcome. Trial registration The trial was registered at ClinicalTrial.gov (identifier NCT01896024).
ISSN:1747-597X